(Q48549299)

English

A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer

scientific article published on 9 November 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/22072307

A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/22072307

phase II clinical trial

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Laura J. Havrilesky

10

object named as

Laura J Havrilesky

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/22072307

Angeles Alvarez Secord

1

object named as

Angeles Alvarez Secord

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/22072307

9

object named as

Fidel A Valea

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/22072307

Andrew Berchuck

2

object named as

Andrew Berchuck

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/22072307

Lawrence R Nycum

4

object named as

Lawrence R Nycum

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/22072307

6

object named as

Larry E Puls

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/22072307

George S Lewandowski

8

object named as

George S Lewandowski

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/22072307

author name string

Robert V Higgins

3

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/22072307

Matthew F Kohler

5

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/22072307

Robert W Holloway

7

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/22072307

language of work or name

0 references

publication date

9 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/22072307

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/22072307

118

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/22072307

13

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/22072307

3283-3293

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/22072307

Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

Second-line treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

Relationships between the structure of taxol analogs and their antimitotic activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

Reliability and validity of the functional assessment of cancer therapy-ovarian.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

Use of tumour markers in monitoring the course of ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

21 January 2018

Docetaxel administered on a weekly basis for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel--ANZGOG 02-01

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26610

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.26610

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/22072307

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/22072307

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48549299&oldid=2201681352"